Navigation Links
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Date:2/10/2009

erapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL(R) CONSTA(R) and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL(R) CONSTA(R). Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL(R) CONSTA(R) and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

Some people taking RISPERDAL(R) CONSTA(R) may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect can be reduced or it may go away over time.

RISPERDAL(R) CONSTA(R) may affect your alertness or driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL(R) CONSTA(R) should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizure
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
3. HHS Issues First Department-Wide Report on Personalized Health Care
4. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
5. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
9. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... CHARLOTTESVILLE, Virginia , September 2, 2015 ... sponsoring of the winners of the 2015 BeHEARD science ... Institute that offers rare disease researchers, access to the ... will use its drug repositioning and pathway analytics capability ... at Wylder Nation Foundation in the study of Niemann-Pick ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... China , May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... and distributor in China of glucose and starch ... that it issued financial results for the third quarter of ... before the opening of the stock,market in USA on ...
... ,, PLEASANTON, Calif. , May 17 TriReme ... for an expanded matrix of sizes for its GliderXtreme™ PTA balloon ... lesions in the peripheral vasculature in balloon diameters from 2.0 – ... , , ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it ... to prevent attacks of hereditary angioedema (HAE), with West Pharmaceutical Services, ... simple-to-use reconstitution device and accompanying training materials will be widely available ... , , ...
Cached Biology Technology:Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 2Shengtai Pharmaceutical Schedules Fiscal Year 2010 Third Quarter Financial Results Conference Call 3TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 2ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 3ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 4ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human]) 5
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... gone underground to get the most top secret information ... in his experimental orchards, and it is sort of ... is part of a national specialty crop research project ... Texas AgriLife Research horticultural scientist, will focus on pecans ...
... causes temperatures to increase in Hawaii,s mountains, deadly ... the mountains, invading most of the last disease-free ... and remarkable birds. A just-published U.S. ... a forthcoming "disease invasion" by examining the present ...
... around the world will convene at the University of ... from the most ambitious effort ever undertaken to measure ... they contribute in the near term to the dramatic ... two-year international field campaign known as POLARCAT was conducted ...
Cached Biology News:Getting to the root of science in a nutty way 2Jeepers creepers: Climate change threatens endangered honeycreepers 2Jeepers creepers: Climate change threatens endangered honeycreepers 3Spring agricultural fires have large impact on melting Arctic 2Spring agricultural fires have large impact on melting Arctic 3
...
... (For small quantities of solvents with DNA ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... 1 Block MBS Start up kit. Includes ... and choice of 1 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: